Subsequently, BRAF inhibition combined with the MEK inhibitor trametinib has shown a decrease in proliferation of tumor cells in vitro and in preclinical xenograft models and produced a dramatic response in a refractory papillary craniopharyngioma case [41, 42]. This evidence concerns the gene MAP2K7 and neoplasm.